Does the media refer more to MMSI or NEOG?

In the previous week, Merit Medical Systems had 1 more articles in the media than Neogen. MarketBeat recorded 3 mentions for Merit Medical Systems and 2 mentions for Neogen. Merit Medical Systems' average media sentiment score of 1.36 beat Neogen's score of 0.97 indicating that Merit Medical Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merit Medical Systems 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, NEOG or ICUI?

ICU Medical has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neogen $870.56M 2.40 -$1.09B -$2.80 N/A ICU Medical $2.23B 1.66 $730K $1.85 80.15

Is NEOG or ICUI more profitable?

ICU Medical has a net margin of 2.15% compared to Neogen's net margin of -69.93%. ICU Medical's return on equity of 7.50% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets Neogen -69.93% 2.35% 1.46% ICU Medical 2.15% 7.50% 3.91%

Does the media favor NEOG or ICUI?

In the previous week, ICU Medical had 3 more articles in the media than Neogen. MarketBeat recorded 5 mentions for ICU Medical and 2 mentions for Neogen. Neogen's average media sentiment score of 0.97 beat ICU Medical's score of 0.80 indicating that Neogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ICU Medical 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, HAE or NEOG?

Haemonetics has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Haemonetics $1.33B 2.63 $97.31M $2.02 38.29 Neogen $870.56M 2.40 -$1.09B -$2.80 N/A

Is HAE or NEOG more profitable?

Haemonetics has a net margin of 7.29% compared to Neogen's net margin of -69.93%. Haemonetics' return on equity of 27.30% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets Haemonetics 7.29% 27.30% 9.59% Neogen -69.93% 2.35% 1.46%

Does the media refer more to HAE or NEOG?

In the previous week, Haemonetics had 1 more articles in the media than Neogen. MarketBeat recorded 3 mentions for Haemonetics and 2 mentions for Neogen. Neogen's average media sentiment score of 0.97 beat Haemonetics' score of 0.38 indicating that Neogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NEOG or XRAY?

In the previous week, DENTSPLY SIRONA had 1 more articles in the media than Neogen. MarketBeat recorded 3 mentions for DENTSPLY SIRONA and 2 mentions for Neogen. DENTSPLY SIRONA's average media sentiment score of 1.14 beat Neogen's score of 0.97 indicating that DENTSPLY SIRONA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DENTSPLY SIRONA 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NEOG or STAA more profitable?

STAAR Surgical has a net margin of -7.24% compared to Neogen's net margin of -69.93%. STAAR Surgical's return on equity of 3.31% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets Neogen -69.93% 2.35% 1.46% STAAR Surgical -7.24% 3.31% 2.55%

Does the media prefer NEOG or STAA?

In the previous week, STAAR Surgical had 3 more articles in the media than Neogen. MarketBeat recorded 5 mentions for STAAR Surgical and 2 mentions for Neogen. Neogen's average media sentiment score of 0.97 beat STAAR Surgical's score of 0.54 indicating that Neogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive STAAR Surgical 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neogen (NEOG) Competitors

$9.58 +0.07 (+0.74%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$9.59 +0.01 (+0.10%)

As of 06/26/2026 07:28 PM Eastern

Compare

NEOG vs. MMSI, ICUI, HAE, XRAY, and STAA

Should you buy Neogen stock or one of its competitors? MarketBeat compares Neogen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neogen include Merit Medical Systems (MMSI), ICU Medical (ICUI), Haemonetics (HAE), DENTSPLY SIRONA (XRAY), and STAAR Surgical (STAA). These companies are all part of the "health care supplies" industry.

How does Neogen compare to Merit Medical Systems?

Merit Medical Systems (NASDAQ:MMSI) and Neogen (NASDAQ:NEOG) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Merit Medical Systems currently has a consensus price target of $92.80, suggesting a potential upside of 29.37%. Neogen has a consensus price target of $10.67, suggesting a potential upside of 11.34%. Given Merit Medical Systems' stronger consensus rating and higher possible upside, equities research analysts plainly believe Merit Medical Systems is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merit Medical Systems	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Merit Medical Systems had 1 more articles in the media than Neogen. MarketBeat recorded 3 mentions for Merit Medical Systems and 2 mentions for Neogen. Merit Medical Systems' average media sentiment score of 1.36 beat Neogen's score of 0.97 indicating that Merit Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merit Medical Systems	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Merit Medical Systems has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Neogen has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

Merit Medical Systems has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merit Medical Systems	$1.52B	2.82	$128.49M	$2.31	31.05
Neogen	$870.56M	2.40	-$1.09B	-$2.80	N/A

Merit Medical Systems has a net margin of 9.03% compared to Neogen's net margin of -69.93%. Merit Medical Systems' return on equity of 13.54% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merit Medical Systems	9.03%	13.54%	7.94%
Neogen	-69.93%	2.35%	1.46%

99.7% of Merit Medical Systems shares are owned by institutional investors. Comparatively, 96.7% of Neogen shares are owned by institutional investors. 0.7% of Merit Medical Systems shares are owned by company insiders. Comparatively, 0.6% of Neogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Merit Medical Systems beats Neogen on 15 of the 16 factors compared between the two stocks.

How does Neogen compare to ICU Medical?

Neogen (NASDAQ:NEOG) and ICU Medical (NASDAQ:ICUI) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

ICU Medical has a net margin of 2.15% compared to Neogen's net margin of -69.93%. ICU Medical's return on equity of 7.50% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-69.93%	2.35%	1.46%
ICU Medical	2.15%	7.50%	3.91%

96.7% of Neogen shares are owned by institutional investors. Comparatively, 96.1% of ICU Medical shares are owned by institutional investors. 0.6% of Neogen shares are owned by company insiders. Comparatively, 2.1% of ICU Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Neogen presently has a consensus price target of $10.67, indicating a potential upside of 11.34%. ICU Medical has a consensus price target of $168.40, indicating a potential upside of 13.58%. Given ICU Medical's stronger consensus rating and higher probable upside, analysts clearly believe ICU Medical is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
ICU Medical	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

In the previous week, ICU Medical had 3 more articles in the media than Neogen. MarketBeat recorded 5 mentions for ICU Medical and 2 mentions for Neogen. Neogen's average media sentiment score of 0.97 beat ICU Medical's score of 0.80 indicating that Neogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ICU Medical	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ICU Medical has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$870.56M	2.40	-$1.09B	-$2.80	N/A
ICU Medical	$2.23B	1.66	$730K	$1.85	80.15

Neogen has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, ICU Medical has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

Summary

ICU Medical beats Neogen on 13 of the 17 factors compared between the two stocks.

How does Neogen compare to Haemonetics?

Haemonetics (NYSE:HAE) and Neogen (NASDAQ:NEOG) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Haemonetics has a net margin of 7.29% compared to Neogen's net margin of -69.93%. Haemonetics' return on equity of 27.30% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.29%	27.30%	9.59%
Neogen	-69.93%	2.35%	1.46%

Haemonetics has higher revenue and earnings than Neogen. Neogen is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	2.63	$97.31M	$2.02	38.29
Neogen	$870.56M	2.40	-$1.09B	-$2.80	N/A

Haemonetics currently has a consensus price target of $78.33, suggesting a potential upside of 1.29%. Neogen has a consensus price target of $10.67, suggesting a potential upside of 11.34%. Given Neogen's higher possible upside, analysts clearly believe Neogen is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 96.7% of Neogen shares are held by institutional investors. 2.1% of Haemonetics shares are held by company insiders. Comparatively, 0.6% of Neogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Haemonetics had 1 more articles in the media than Neogen. MarketBeat recorded 3 mentions for Haemonetics and 2 mentions for Neogen. Neogen's average media sentiment score of 0.97 beat Haemonetics' score of 0.38 indicating that Neogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Haemonetics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Neogen has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market.

Summary

Haemonetics beats Neogen on 14 of the 17 factors compared between the two stocks.

How does Neogen compare to DENTSPLY SIRONA?

Neogen (NASDAQ:NEOG) and DENTSPLY SIRONA (NASDAQ:XRAY) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

96.7% of Neogen shares are owned by institutional investors. Comparatively, 95.7% of DENTSPLY SIRONA shares are owned by institutional investors. 0.6% of Neogen shares are owned by company insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

DENTSPLY SIRONA has a net margin of -17.06% compared to Neogen's net margin of -69.93%. DENTSPLY SIRONA's return on equity of 18.83% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-69.93%	2.35%	1.46%
DENTSPLY SIRONA	-17.06%	18.83%	5.13%

DENTSPLY SIRONA has higher revenue and earnings than Neogen. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$870.56M	2.40	-$1.09B	-$2.80	N/A
DENTSPLY SIRONA	$3.68B	0.60	-$598M	-$3.15	N/A

Neogen has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market. Comparatively, DENTSPLY SIRONA has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

In the previous week, DENTSPLY SIRONA had 1 more articles in the media than Neogen. MarketBeat recorded 3 mentions for DENTSPLY SIRONA and 2 mentions for Neogen. DENTSPLY SIRONA's average media sentiment score of 1.14 beat Neogen's score of 0.97 indicating that DENTSPLY SIRONA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DENTSPLY SIRONA	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neogen currently has a consensus target price of $10.67, suggesting a potential upside of 11.34%. DENTSPLY SIRONA has a consensus target price of $13.55, suggesting a potential upside of 23.03%. Given DENTSPLY SIRONA's higher possible upside, analysts clearly believe DENTSPLY SIRONA is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
DENTSPLY SIRONA	3 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

DENTSPLY SIRONA beats Neogen on 9 of the 16 factors compared between the two stocks.

How does Neogen compare to STAAR Surgical?

Neogen (NASDAQ:NEOG) and STAAR Surgical (NASDAQ:STAA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

Neogen has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market. Comparatively, STAAR Surgical has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

STAAR Surgical has lower revenue, but higher earnings than Neogen. STAAR Surgical is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$870.56M	2.40	-$1.09B	-$2.80	N/A
STAAR Surgical	$290.38M	5.02	-$80.45M	-$0.43	N/A

In the previous week, STAAR Surgical had 3 more articles in the media than Neogen. MarketBeat recorded 5 mentions for STAAR Surgical and 2 mentions for Neogen. Neogen's average media sentiment score of 0.97 beat STAAR Surgical's score of 0.54 indicating that Neogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STAAR Surgical	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of Neogen shares are owned by institutional investors. Comparatively, 96.7% of STAAR Surgical shares are owned by institutional investors. 0.6% of Neogen shares are owned by company insiders. Comparatively, 39.9% of STAAR Surgical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

STAAR Surgical has a net margin of -7.24% compared to Neogen's net margin of -69.93%. STAAR Surgical's return on equity of 3.31% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-69.93%	2.35%	1.46%
STAAR Surgical	-7.24%	3.31%	2.55%

Neogen currently has a consensus target price of $10.67, indicating a potential upside of 11.34%. STAAR Surgical has a consensus target price of $27.81, indicating a potential downside of 5.04%. Given Neogen's stronger consensus rating and higher possible upside, analysts plainly believe Neogen is more favorable than STAAR Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
STAAR Surgical	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09

Summary

STAAR Surgical beats Neogen on 9 of the 16 factors compared between the two stocks.

Get Neogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEOG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEOG vs. The Competition

Export

Metric	Neogen	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.07B	$8.45B	$6.70B	$12.22B
Dividend Yield	N/A	2.49%	2.67%	6.12%
P/E Ratio	-3.42	15.91	25.76	24.17
Price / Sales	2.40	7.83	559.40	100.03
Price / Cash	1.65	17.55	46.99	54.37
Price / Book	1.00	3.36	10.77	6.35
Net Income	-$1.09B	$226.25M	$3.57B	$337.63M
7 Day Performance	2.90%	0.44%	2.15%	0.06%
1 Month Performance	4.13%	-1.93%	1.06%	-0.15%
1 Year Performance	102.54%	0.80%	34.16%	27.55%

Neogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEOG Neogen	1.5057 of 5 stars	$9.58 +0.7%	$10.67 +11.3%	+100.0%	$2.07B	$870.56M	N/A	2,110	News Coverage High Trading Volume
MMSI Merit Medical Systems	4.3457 of 5 stars	$66.50 -1.1%	$92.80 +39.5%	-22.7%	$4.01B	$1.54B	28.79	7,500	Positive News
ICUI ICU Medical	3.4486 of 5 stars	$136.14 -3.0%	$168.40 +23.7%	+13.5%	$3.51B	$2.23B	73.59	13,000	News Coverage Positive News
HAE Haemonetics	1.9603 of 5 stars	$72.56 -2.2%	$78.33 +8.0%	+3.4%	$3.37B	$1.33B	35.92	3,009	Analyst Upgrade
XRAY DENTSPLY SIRONA	4.5504 of 5 stars	$10.15 -1.7%	$13.55 +33.5%	-31.2%	$2.07B	$3.68B	N/A	14,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEOG) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neogen (NEOG) Competitors

NEOG vs. MMSI, ICUI, HAE, XRAY, and STAA

How does Neogen compare to Merit Medical Systems?

Summary

How does Neogen compare to ICU Medical?

Summary

How does Neogen compare to Haemonetics?

Summary

How does Neogen compare to DENTSPLY SIRONA?

Summary

How does Neogen compare to STAAR Surgical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEOG vs. The Competition

Neogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neogen (NEOG) Competitors

NEOG vs. MMSI, ICUI, HAE, XRAY, and STAA

How does Neogen compare to Merit Medical Systems?

Do analysts recommend MMSI or NEOG?

Does the media refer more to MMSI or NEOG?

Which has more volatility and risk, MMSI or NEOG?

Which has stronger earnings and valuation, MMSI or NEOG?

Is MMSI or NEOG more profitable?

Do institutionals and insiders have more ownership in MMSI or NEOG?

Summary

How does Neogen compare to ICU Medical?

Is NEOG or ICUI more profitable?

Do institutionals and insiders have more ownership in NEOG or ICUI?

Do analysts rate NEOG or ICUI?

Does the media favor NEOG or ICUI?

Which has stronger earnings and valuation, NEOG or ICUI?

Which has more volatility and risk, NEOG or ICUI?

Summary

How does Neogen compare to Haemonetics?

Is HAE or NEOG more profitable?

Which has preferable earnings & valuation, HAE or NEOG?

Do analysts prefer HAE or NEOG?

Do institutionals & insiders believe in HAE or NEOG?

Does the media refer more to HAE or NEOG?

Which has more volatility and risk, HAE or NEOG?

Summary

How does Neogen compare to DENTSPLY SIRONA?

Do institutionals and insiders hold more shares of NEOG or XRAY?

Is NEOG or XRAY more profitable?

Which has higher earnings & valuation, NEOG or XRAY?

Which has more risk & volatility, NEOG or XRAY?

Does the media favor NEOG or XRAY?

Do analysts prefer NEOG or XRAY?

Summary

How does Neogen compare to STAAR Surgical?

Which has more volatility and risk, NEOG or STAA?

Which has higher valuation and earnings, NEOG or STAA?

Does the media prefer NEOG or STAA?

Do institutionals & insiders believe in NEOG or STAA?

Is NEOG or STAA more profitable?

Do analysts prefer NEOG or STAA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEOG vs. The Competition

Neogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools